Novanta closed its largest deal in late July, buying Riverpoint Medical in a cash transaction that management sized near $1 billion at close. A separate milestone of $250 million is due in early 2027. The purchase is the company's attempt to turn a precision-components supplier into a more medical, more recurring platform. The second-quarter print that preceded the close was the strongest organic growth period since early 2023. That sequence is why the market is willing to debate quality rather than survival. The investment question is whether a high-multiple surgical-consumables asset upgrades mix enough to justify a still-rich valuation after equity dilution and a sharp leverage step-up.
Automation Enabling Technologies carried the quarter. That segment grew about 12 percent and widened gross margin on Physical AI work, warehouse robotics, and laser tools used in probe-card and advanced-packaging lines. Medical Solutions grew as well, yet its gross margin compressed and its book-to-bill, the ratio of orders taken to shipments billed, slipped below one. Companywide adjusted earnings before interest, taxes, depreciation, and amortization, a cash-earnings proxy that strips certain items, still expanded faster than sales. The split is the whole story: industrial precision is funding the print while the medical franchise is being rebuilt around consumables that have not yet appeared in the reported quarter.
Reported sales rose about 10 percent to roughly $266 million. Adjusted cash earnings grew faster, and first-half operating cash flow already exceeded the whole of the prior year. Management now guides a third-quarter sales band above $300 million after folding Riverpoint into the outlook. The next several quarters resolve whether Medical Solutions margins stabilize, whether Riverpoint's private-label sutures and anchors actually double the consumables mix, and whether net leverage comes back down from the post-close step-up. If those three do not move together, the multiple is paying for a mix upgrade that exists only in the deal slides.